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Ob*dws . The purpose of this study was to compare the edicts
of very early ( :5 1 .5 h after symptom oelet) and later (>1 .5 up to
4 h) thrombolytic therapy on infarct size, left ventricular function
and early mortality In patients with acute myocardial infarction .
To start dwambolysis at the eadlest
possible
moment, it was
performed In the prehospital setting. A cutoff time of 1,5 h was
vely stipulated .
Shortening of ischemic time is crucial within the
lot 2 h. : reholgM thimmillolysis can reduce time to treatment and
tuables very early initiation of therapy for many patients.
MAU& One hundred seventy patients received 30 mg of
anistreplase up to 4 h from symptom and by a mobile intensive
care unit physician. Infarct size was measured from cumulative
release of alpha-hydroxybutyrate dehydrolewnl4 and left ventric .
ular function was assessed by contrast anglograms 10 days after
the infarction .
Intravenous administration of thrombolytic agents in acute
myocardial infarction has been shown to limit infarct size
(1,2), preserve left ventricular function (l .-3) and improve
survival (4-7) . Very early treatment has the potential to
maximize these beneficial effects (4,8-10) . However, rela-
tively few patients are treated in the hospital within the 1st
60 to 90 min of evolving infarction, Therefore, since the early
190 (8,9) some centers have initiated thrombolytic therapy
in the mobile intensive care unit or in the patient's home
Controlled studies subsequently demonstrated the feasibil-
ity, safety and significant time-saving value of prehospital
thrombolysis (11-15) . On the basis of the results of a pilot
study (11), prehospital thrombolysis has been performed by
emergency physicians in six of the seven mobile intensive
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Results. The decision to treat on scene was correct in 98% of
patients . There were no Weeding complications or deaths outside
the hospital setting. t o 28 patients (17%) the isehemic process was
Interrupted . Findings with thrombolytic therapy initiated s:11 .5
(96 patients) versus > 1 .5 h (74 patients) were the following: initial
extent of epleardial injury, 1 .6 it 0.9 versus 1 .4 * 0.7 mV, p =
N&, infarct size by cardiac enzyme release 646 it 634 versus
:t 712 Miter, p < 0 .05; ejection fraction 57 t 14% versus
51 it 1316, p < 0.05; regionaldyssynevgic am 24 it 22 versus 33 t
24 U, p < 0,05 ; 21-day mortality 1 of 96 versus S of 74 patients
(1% vs. 7%, p < 0 .05) .
Conclusions . The data suggest that in evolving myocardial
infarction up to 4 h in duration, the start of thrombolytic therapy
at sid h compared with >1.5 h limits infarct size, preserves left
ventricular function and may save lives.
(J Am Coll Cardiol 1993,22 :1304-10)
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care units on a routine basis since 1987 in West Berlin
(16,17) .
When deliberating in 1988 how to prove benefit from
prehospital thrombolysis, we had to consider that a random-
ized study comparing thrombolytic therapy initiated before
or after hospital admission was no longer possible because
most emergency physicians were already convinced of this
benefit . It was therefore decided to compare the effects of
very early versus later thrombolytic therapy by applying
stipulated cutoff time of 1 .5 h. Compared with in-hospital
initiation of therapy, a much larger proportion of all patients
with acute myocardial infarction in Berlin had been candi-
dates for, and actually received, very early thrombolytic
therapy in the prehospital setting (16,17) . Thus, benefit from
very early thrombolytic therapy may indirectly provide
evidence of benefit from prehospital thrombolytic therapy .
Methods
This study was initiated in late 1988 by the Klinikum
Steglitz and Krankenhaus Neuk6lin, serving two of seven
mobile intensive care units in Berlin, each staffed with 'ine
emergency physician and two emergency medical techni-
cians. Patients with symptoms typical for evolving myocar-
dial infarction and diagnostic ST segment elevation on a
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12-lead electrocardiogram (ECG) of at least 0 .1 mV in two
limb leads or 0 .2 mV in two contiguous chest leads were
eligible, provided that intravenous thrombolytic therapy
could be initiated within 4 h of symptom onset . Exclusion
criteria were age >75 years and usual contraindications for
thrombolytic therapy, in addition to cardiogenic shock, left
bundle branch block on the initial ECG, severe concomitant
diseases and inability to provide informed consent for throm-
bolytic therapy in the mobile intensive care unit . In response
to the results of the Second international Study of Infarct
Survival (5), the initial upper age limit was abandoned for the
last 70 patients .
After recording the first ECG, nitroglycerin was admin-
istered sublingually, a venous line inserted, appropriate
circulatory support given and morphine or diazepam injected
as needed . When ST elevation persisted on a second ECG
recording, blood samples were drawn, ant thrombolytic
therapy was started . Clinical status, complications and time
intervals were recorded on a special report form .
Drug regimen . Anistreplase (30 mg) was injected intra-
venously for 3 to S min, preceded by 100 mg of methyl-
prednisolone. In the hospital, 250 mg of acetylsalicylic acid
was given orally or intravenously, followed by 100 mg orally
daily . Intravenous heparin was started after 6 h with a dose
of 800 IU/h that was then adjusted to maintain the activated
partial thromboplastin time at I .5 to 2 times normal . Heparin
infusion was continued for at least 3 days .
Study end points . Prospectively defined primary study
end points were 1) complications and side effects of prehos-
pital injection of 30 mg of anistreplase in the prehospital
setting and during the hospital stay ; and 2) comparison of
enzyme-determined infarct size and left ventricular function
at day 10 in patients treated :51 .5 h and >1 .5 h after
symptom onset. Secondary end points were 1) patency and
degree of stenosis at day 10, 2) incidence of reischemia and
reinfarction and 3) 21-day mortality .
Electrocardiographic analysis . The size of the ischemic
area at risk was defined as the sum of ST segment elevation
and depression 20 ms after the J point . The extent of the
initial epicardial injury was also quantified by counting the
number of leads with ST elevation a.-O. I mV (18) .
Three patients with anterior myocardial infarction were
excluded from ST segment measurements because of right
bundle branch block, and in another nine patients the initial
ECGs were not suitable for quantitative analysis owing to
baseline undulations or other artifacts .
Enzyme analysis. Serum enzyme activity was measured
by means of the alpha-hydroxybutyrate dehydrogenase
(HBDH) opt . monotest and creatinine kinase (CK)-NAC akt .
monotest, respectively (Boehringer-Mannheim) . The upper
normal value for HBDH is 140 Miter and 80 Miter for CK .
The HBDH level was measured at baseline and 12, 24, 36, 48,
60, 72, 96 and 120 h after the onset of symptoms. The
cumulative release of HBDH was determined centrally, as
previously described by De Zwaan et al . (19). Significant
HBDH release was assumed only when the maximal value on
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the time-activity curve exceeded the baseline value by at least
40% (e.g., baseline 100 IUAiter, maximum >140 IUAiter) .
Activity curves for HBDH could be evaluated in 151
patients (including 22 patients without significant HBDH
release)
. In 19 patients, I-IBDH curves were either missing or
not evaluable (four early deaths, seven missing samples,
eight hemolysis).
Creatine kinase serum activity was measured at baseline
and at 14, 18 and 24 h
. In addition, in 41 patients (also
participating in a study on enzyme release) CK was mea-
sured every 15 min for the 1st 4 h . Definite myocardial
infarction was defined by a twofold or greater increase in CK
activity above the upper limit of normal .
Quantitative anglographic analysis . Angiography was per-
formed in 141 patients 10 ± 4 days after infarction
. Angio-
graphic studies were unavailable in 9 of 96 patients treated
within 90 min of symptom onset and in 20 of 74 treated later .
Reasons were death in one patient treated early and five
patients treated later and refusal or advanced age in symptom-
free patients in 23 others without angiogrdphic studies .
The percent lumen diameter of the infarct-related coro-
nary artery stenosis was measured with an automated edge
detection system (MIP-D, Kontron) . An infarct-related ar-
tery was judged patent if the perfusion grade was Thrombol-
ysis in Myocardial Infarction trial (TIMI) grade 3 .
Ventriculography was not performed in 1 patient because
of renal failure and was not adequate for quantitative anal-
ysis in 13 patients . Global ejection fraction and regional left
ventricular wall motion abnormalities were evaluated as
previously described (1,8) .
Protocol violation. Protocol was violated in three cases :
one patient had cardiogenic shock and two patients in the
late treatment group had an earlier onset of infarction than
was presumed on the scene (7 and 8 h, respectively) . All
three patients were included in the analysis .
Another two patients had a clear misdiagnosis. One
patient with anterior ST segment elevation had severe left
ventricular hypertrophy from aortic valve stenosis and acute
pulmonary edema; the other had inferior ST elevation due to
acute alcoholic pancreatitis . Both suffered no harm from
prehospital thrombolytic therapy . They were excluded from
further analysis .
Statistical analysis. Group differences were assessed by
the separate variance estimate t or chi-square test for con-
tinuous or dichotomous variables, respectively. Two-tailed
p values < 0.05 were considered significant . In-hospital
mortality was subjected to stepwise multivariate logistic
regression (BMDP LIZ). Variables entered were early and
late treatment, gender, age (560 and >60 years), history of
diabetes, hypertension, previous myocardial infarction and
location of index infarction (Table 1) . All variables are
expressed as mean value ± SD .
On the basis of the findings of time-dependent differences
in HBDH release in a previous study (20) for an assumed
significant difference in HBDH release of 30% between the
early and the late treatment groups, tile necessary sample
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Table 1 . Baseline Characteristics
Values presented are mean value t SD or number (%) .
size was estimated to be -100. After inclusion of this
number of patients there was a significant difference in
HBDH release but not for left ventricular function . Thus, it
was decided to prolong patient enrollment for another year .
The study protocol was approved by the Ethical Committee
of the Klinikum Steglitz, Free University of Berlin .
Results
Patient chamcteristks (Tables 1 and 2) . Between late 1988
and mid-1990, 170 patients were enrolled in the study . On
average, 25 min was needed to start thrombolytic therapy . In
96 patients (56%), thrombolysis could be initiated within
1 .5 h (in 50 within I h) (early treatment group) and in 74
between >1 .5 and 4 h after symptom onset (late treatment
group) (Fig . 1). There was no difference in medical history
and index infarct location between the two groups . There
were more women in the late treatment group . The mean
time interval between onset of symptoms and emergency call
was 73 ± 49 min for women and 54 ± 48 min for men (p =
103), Because the mean Me was 65 ± 10 years for women
and 59 :t I I years for men (p = 0.002), the average age was
higher in the late treatment group . Of 13 patients >75 years
Table 2. Time Intervals
Values presented are mean value
± SD. ICU
= intensive care unit (in the
hospital)
.
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old, 7 were women, and all were in the late treatment group .
Of the six older men, three were treated early and three late .
Critical events (Table 3) . Prehospital ventricular fibrilla-
tion occurred four times before and four times after injection
of anistreplase and was treated successfully by defibrillation
in all patients. Symptomatic bradycardia in nine patients
(severe sinus bradycardia in six and second- or third-degree
atrioventricular block in three) was managed by intravenous
atropine and in three patients by temporary pacing . Hypo-
tension after anistreplase injection, as previously defined in
the APSAC Intervention Mortality Study (6), occurred in 19
patients . All received intravenous fluids, and catecholamines
were given additionally in 11 . Minor allergic reactions, such
as shivering and rash, occurred in three patients .
There were no bleeding complications or deaths outside
the hospital setting . The 21-day mortality rate was 31% .
One patient in the early treatment group and 5 in the late
treatment group (including I of the 13 patients >75 years old)
died (p < 0 .05). Multivariate analysis revealed only time to
thrombolytic therapy as a significant independent predictor
of mortality at 21 days . Causes of death were cardiogenic
shock in four patients, cardiac rupture in one and sudden
death on day 5 in one .
Interrupted iscbemic events (Table 4, Fig . 2). An enzyme
release typical for myocardial infarction was observed in 140
patients . In 129, HBDH increased significantly, and in I I
with insufficient HBDH samples, CK increased at least
fourfold. Of 30 patients without a significant increase in
cardiac enzymes, 28 had a persistent significant ST segment
elevation in the prehospital ECG . The CK time-activity
curve showed a slight increase not exceeding twice the upper
limit of normal in 19 patients and was classified as an
"interrupted ischemic event ." It remained flat in nine and
was classified as a "probable interrupted ischemic event ."
Two patients had only a slight ST segment elevation and no
CK increase . Their condition was probably misdiagnosed
because the final diagnosis remained unclear . Considering
also the two clearly misdiagnosed and therefore excluded
patients (see Methods section on protocol violation), the
decision to initiate thrombolysis on the scene was correct in
168 (98%) of 172 patients . Angiography was performed in 22
patients, and 21 had coronary artery lesions . Only one
patient (one of the two with a probable misdiagnosis) had
apparently normal coronary arteries on angiography .
Infarct size (Table 5). The cumulative HBDH release was
751 ± 669 lU/liter in all patients . The level was significantly
lower in the early treatment group, even when only patients
with definite HBDH release were evaluated . The maximal
CK value was only insignificantly lower in the early treat-
ment group .
Angiographic findings at day 10 (Tables 6 to 8). Global
and regional ejection fraction were significantly improved in
the early treatment group . The overall patency rate was 71%
(100 of 141 patients). In the early treatment group, there was
a trend toward a higher patency rate and a significantly larger
proportion of residual stenosis <50% . The mean diameter
Time to Treatment
03 h
(n = to
>15 h
(n = 74) p Value
Age (yr) 58 ±11 64 ± 10 < 0 .001
Female 16 (11) D (31) < 0 .05
Infarct location
Anterior 45(47) 36 (49)
Inferior 51(53) 38(51) NS
History
Hypertension 27(28) 24(32) NS
Diabetes 12(13) 12(l6) NS
Previous infarction 14(15) 17(23) NS
Time to Treatment
All Patients sl,5 h >1.5 h
Onset of symptoms to
ambulance call (min)
58 t 30 25 t 16 103 ± 43
Ambulance call to arrival
M patient's site (min)
12 6 12±6 13±7
Duration until anistreplase
injection (min)
25 10 25 ± 11 26 ± 10
Transportation time to
ICU (min)
22 9 23 ± 10 22 t 8
Symptom onset to start of
%mbolysis (h)
1.7 0.8 1 .0 ± 0.3 2 .5 ± 1 .1
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Figure 1 . Frequency distribution of the time
between onset of symptoms and start of throm-
bolysis. Bars represent relative frequency dis-
tribution ; solid circles represent cumulative
frequency distribution . Pts . = patients.
100
Z Pta .
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80 -1
70 -~
60 ~
50 -
40 -
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20 -1
stenosis in patients with significant lesions was not different
(59 ± 9% in the early treatment group and 58 ± 8% in the late
treatment group) .
In 'Table 7 data are provided with respect to patency of
the infarct-related artery . Vessel patency was associated
with a significantly better left ventricular function than that
associated with persistent vessel occlusion, and there was a
strong trend toward a smaller enzyme-determined infarct
size in the group with a patent infarct-related artery . When
eurly and late treatment were compared in patients with
persistent patency, no significant difference in left
ventricular function could be demonstrated, and the 24%
difference in enzyme-determined infarct size was not statis-
tically significant (Table 8) .
Discussion
In Berlin, prehospital thrombolysis has been performed
routinely since 1987 (16,17). Most patients in the hospital
Table 3. Critical Events
10 _+
0 -
Onset of pain to
treatment [min]
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because of acute myocardial infarction make use of the
mobile intensive care unit . More than one half are seen first
by the primary care physician outside the hospital setting
within 1 .5 h from symptom onset and therefore are candi-
dates for very early thrombolytic therapy (17) .
The present study was undertaken to prove the benefit
obtained from very early thrombolysis by using a prospec-
tively stipulated cutoff point of 1 .5 h. Enzyme-determined
infarct sb e was significantly smaller, left ventricular func-
tion at day 10 significantly better and early mortality signif-
icantly lower in the early treatment group . As in previous
studies (9,10,12-14,21,22), thrombolysis in the prehospital
setting was safe . As with in-hospital thrombolysis (23),
treatment of a few misdiagnosed patients is unavoidable
when overall benefit from speedy thrombolysis is to be
achieved .
Infarct size and preservation of left ventricular function .
Direct effects of thrombolytic therapy in terms of limitation
of infarct size may be evaluated by quantitative measure-
ments of cardiac enzyme release (1,2,10,20), whereas the use
of maximal CK activity as an index of infarct size (14,22)
may be less appropriate, because this measure is known to
be further elevated by effective thrombolysis (1) . The
amount of cumulative HBDH release in our study was
similar to that in the active treatment groups of two larger
Table 4. Patients without Significant Increase ofCardiac Enzymes
Time to Treatment
:51 .5 h >1 .5 h
No . % No .
%
Prehospital
Ventricular fibrillation 6
6 2 3
Hypotension
I 1 8 1
Bradycardia 7
7 2 3
Allergy 2
2 1 1
In the hospital
Death
I I
5 7
Reinfarction
4 4 4 5
Reischemia 8 8
5 6
Bleeding
5 5 3 4
Coronary angioplasty
25 26 19
26
Coronary artery bypass grafting 10 10
9 12
Time to Treatment
S13 h
>1 .5 h
No. No .
%
Total
18 19
12 16
Interrupted isehemic event
10
10 9 12
Probably interrupted ischemic event
7 7 2
2
Probable misdiagnosis
1 1 1
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controlled thrombolysis trials and clearly less than in the
corresponding control groups (2,20) . The difference in en-
zyme-determined infarct size of 27% in favor of the early
treatment group in the present study fits well with the
time-dependent decreasing magnitude of limitation of infarct
size in controlled studies, where data subdivided by time
from symptom onset are provided for the 1st 3 to 4 h
(1,11,20) .
The issue of preservation of left ventricular function is
more complex (24-27). Improved function several days after
the acute event depends not only on direct salvage of
myocardium but, in addition, on whether sustained patency
of the infarct-related artery is achieved, preventing infarct
expansion and left ventricular dilation (27-30) .
As evidenced by the data in Tables 7 and 8, improved left
T S . Comparison of Infarct Size
CK - creatine
kinase; HBDH = cumulative alpha-hydroxybutyrate
deh
release ; HBDH increased = cumulative HBDH release in
patients with significant enzyme increase
; Pts = number of patients; BST =
sum of
ST segment elevation and depression in the prehospital electrocardio-
gram; ST
t
= ST segment elevation
.
0 ! f
0 1 2 3
4
10
16 22 28
1 Start drowtng samples
(hrs]
1 .3 hrs after onset of palm
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Figure 2 . Serial creatine kinase (CPK) measurements in
a patient with an interrupted ischemic event .
ventricular function at day 10 in the early treatment group is
related mainly to a larger proportion of patients with a patent
infarct-related artery and to a lesser extent to actual salvage
of ischemic myocardium. Studies in which thrombolysis was
initiated before or after hospital admission also showed
improved left ventricular function when prehospital throm-
bolysis was associated with a higher patency rate at the time
of later catheterization (10) but did not show significant
differences when patency rates were the same (14,22) .
In-hospital mortality. There is evidence to suggest that,
as in the present study, early in-hospital mortality is favor-
ably influenced by salvage of ischemic myocardium
(2,3,21,31), whereas left ventricular function after several
days and, thus, later in-hospital and long-term mortality
depend more on vessel patency (25,28,29) . Although great
caution is necessary in interpreting conventionally signifi-
Table 6. Angiographic Findings
IRA = infarct-related artery ; Pts = number of patients ; TIMI = Throm-
bolysis in Myocardial Infarction trial .
Time to Treatment
s1 .5 h >1 .5 h
Mean Value
t SD Pts
Mean Value
± SD Pts
p
Value
Angiography
(day)
II t 5 87 10 t 3 54 NS
13ietaion fraction 57 t 14
81
51 t 13 46 < 0.05
(0/0)
Dyssynergic area
(U)
24 t 22 81 33 t 24
46 < 0.05
IRA TIMI flow
grade 3
65(75%) 35 (65%) NS
Stenosis <50%
14(16%) 20%) < 0.05
Time to Treatment
s1.5 h >1.S h
Mean Value
t SD Pts
Mean Value
t SD Pts
p
Value
2:ST (mV) 1 .6 t 0.9
89 1 .4 t 0.7 69 NS
ST t (no, of
leads)
5.1
t
1 .8 91 4 .7 t 1 .8 70
NS
HBDH (lU0iter) 646 t 634 85 8 6 t 712
66 c 0.05
HBDH increased
(lU/liter)
774 t 618
71 1.01 ± 672 58
< 0.05
Maximal CK
(lulliter)
691 t 659 95 857 t 683 70 NS
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Table 7. Analysis According to Patenc :' of the
Infarct-Related Vessel
Abbreviations as in Tables 5 and 6.
cant mortality differences in small study groups, a finding
similar to that in this study was previously reported for
prehospital thrombolysis (21) and, moreover, a lower mor-
tality in patients treated very early is supported by the
results of large mortality trials (4,5) .
Interrupted ischemic event . In patients with intermittent
or incomplete coronary artery occlusion, thrombolysis may
dissolve the threatening thrombus and thereby interrupt the
ischemic event (8) . In this regard, thrombolysis seems to be
more effective than anticoagulant therapy because 17% of
patients in this study lacked enzyme release compared with
7% of the "placebo" group in the Intravenous Streptokinase
in Acute Myocardial Infarction trial (1) who received vigor-
ous anticoagulant therapy . Because the incidence of inter-
rupted ischemic events was not different between the early
and late treatment groups (Table 4), the time delay may be
less critical .
Limitations of the study . I) The early treatment group
comprised younger patients and fewer women . This major
imbalance was caused by the fact that women with infarctiov
are on average older than men, and delay in time to treat-
ment is longer in women . The multivariate model s, :ected
only time to treatment as an independent predictor of
mortality . Considering the small sample size, however, it
might be questioned whether any multivariate analysis will
Table 8 . Analysis of Patients With a Patent Infarct Vessel
(TIMI 3) by Titne to Treatment
Abbreviations as in Tables 5 and 6 .
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adequately take such imbalance into account . Infarct size,
which is the primary end point . is not related to age or
gender, but, rather, to the initial ischemic area at risk . In this
respect, the trend to a larger sum of initial ST segment
deviations (Table 5) may reflect even potentially larger
infarcts at baseline (18,32) in the early treatment group .
2) Angiographic data are less complete in the late (73%)
compared with the early (91%) treatment group, which was
only partially due to differences in mortality . Because there
was a trend toward higher HBDH release in patients in the
late treatment patients without angiography compared with
those with angiography (1,013 + 997 vs . 858 t 637), we have
no reason to assume that the poorer outcome in terms of left
ventricular function in the late treatment group was due to
the exclusion of patients with smaller infarctions .
Conclusions . For direct salvage of jeopardized myocar-
dium, shortening of ischemic time is critical within the 1st 2 h
(11,15,20), whereas a I -h time gain may generate only marginal
benefit after 3 h . Therefore, the many patients who seek
medical attention very early (P) are entitled to prompt institu-
tion of thrombolytic therapy. This can be effectively provided
for by prehospital initiation of thrombolytic therapy (17) . In the
usual clinical setting, the in-hospital times to treatment still
continue to be long (15,33,34) . However, even if the in-hospital
time delays are substantially shortened, there remains the
transportation time to hospital, which, especially in a rural
environment, may be of major importance .
We thank the medical, nursing and medical technician staff of both mobile
intensive care units and hospital intensive care units for their help during this
study .
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